SVA [SINOVAC BIOTECH] 20-F: None (Title of Class) Indicate the number of

[None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 55,809,661 common shares as of December 31, 2014 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Weidong Yin Weidong Yin Chief Executive Officer EX-13.1 5 a14-26055_1ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Nan Wang Chief Financial Officer EX-13.2 6 a14-26055_1ex13d2.htm EX-13.2] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan of our reports dated April 29, 2015, with respect to] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining the Company’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to the Company’s 2012 Share Incentive Plan of our report dated April 29, 2013 with respect to the consolidated financial]

By | 2016-03-16T06:41:50+00:00 April 29th, 2015|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

QUNR [Qunar Cayman Islands] 6-K: Qunar Announces Promotion of Senior Management Team and

[Qunar Announces Promotion of Senior Management Team and Files Annual Report BEIJING, April 29, 2015 (GLOBE NEWSWIRE) — Qunar Cayman Islands Limited (NASDAQ: QUNR) (“Qunar” or the “Company”), China’s leading mobile and online travel platform, today announced that its board of directors has appointed Ms. Yilu Zhao, previously Chief Strategy Officer of the Company, to Chief Financial Officer of the] [QUNAR CAYMAN ISLANDS LIMITED Sam Hanhui Sun]

By | 2016-03-21T16:12:39+00:00 April 29th, 2015|Categories: Chinese Stocks, QUNR, Webplus ver|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] DEFA14A: SCHEDULE 14A x ¨ Check the appropriate box:

[SCHEDULE 14A x ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. ________________________________________________________ Payment of Filing Fee (Check the appropriate box): x No fee required ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of]

By | 2016-03-25T04:39:09+00:00 April 29th, 2015|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CO [China Cord Blood] 6-K: China Cord Blood Corporation Announces Formation of a

[China Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal HONG KONG, China, April 29, 2015 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated] [FORM 6-K CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Yes o No x Other Events On April 2 9 Description]

By | 2016-03-27T09:13:53+00:00 April 29th, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments
Read More

CHOP [China Gerui Advanced Materials] 6-K: China Gerui Advanced Materials Group Limited Regains Compliance

[China Gerui Advanced Materials Group Limited Regains Compliance with NASDAQ Listing Requirements CHOP ZHENGZHOU, China, April 28, 2015 /PRNewswire-FirstCall/ -- China Gerui Advanced Materials Group Limited ( As previously announced on March 2, 2015 and March 10, 2015, China Gerui received written notices (the "Notices") from the Listing Qualifications department of The NASDAQ Stock Market ("NASDAQ") indicating that the Company] [FORM 6-K CHINA GERUI ADVANCED MATERIALS GROUP LIMITED 1 Shuanghu Development Zone Xinzheng City Zhengzhou, Henan Province China, 451191 þ o o þ CHINA GERUI ADVANCED MATERIALS GROUP LIMITED April 29, 2015 Edward Meng Chief Financial Officer]

By | 2016-04-03T05:26:05+00:00 April 29th, 2015|Categories: Chinese Stocks, CHOP, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results - Conference call scheduled for April 20, 2015 at 8:00 a.m. ET - BEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2014. Fourth] []

By | 2016-03-16T06:43:47+00:00 April 29th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

QUNR [Qunar Cayman Islands] 20-F: (Original Filing)

[* Not for trading, but only in connection with the listing on The NASDAQ Global Market of American depositary shares. Currently, one ADS represents three Class B ordinary shares. None (Title of Class) None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the] [Place of Incorporation Subsidiaries Queen’s Road Investment Management Limited Hong Kong Beijing Qunar Software Technology Company Limited People’s Republic of China Shanghai Qianlima Network Technology Co., Ltd. People’s Republic of China Variable Interest Entity Qunar.com Beijing Information Technology Company Limited People’s Republic of China Subsidiaries of Variable Interest Entity Beijing Jiaxin Haoyuan Information Technology Company Ltd. People’s Republic of China] [I, Chenchao (CC) Zhuang, certify that: 1. I have reviewed this annual report on Form 20-F of Qunar Cayman Islands Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [Certification by the Principal Financial Officer I, Sam Hanhui Sun, certify that: 1. I have reviewed this annual report on Form 20-F of Qunar Cayman Islands Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 EX-13.1 5 a15-6508_1ex13d1.htm EX-13.1] [Certification by the Principal Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29, 2015 EX-13.2 6 a15-6508_1ex13d2.htm EX-13.2] [15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-193539) pertaining to the Qunar Cayman Islands Limited Amended and Restated 2007 Share Plan of our reports dated April 29, 2015, with respect to the consolidated financial statements of Qunar Cayman Islands Limited and the effectiveness of internal]

By | 2016-03-21T16:15:24+00:00 April 29th, 2015|Categories: Chinese Stocks, QUNR, SEC Original|Tags: , , , , , |0 Comments
Read More
Skip to toolbar